Modulation of functionally active endothelin-converting enzyme by chrome neutral endopeptidase inhibition in experimental atherosclerosis

Circulation

Volumn 101, Issue 16, 2000, Pages 1976-1981

  Grantham, J Aaron ^a   Schirger, John A ^a   Wennberg, Paul W ^a   Sandberg, Sharon ^a   Heublein, Denise M ^a   Subkowski, Thomas ^a,b   Burnett Jr , John C ^a  

^a MAYO CLINIC   (United States)

^b BASF SE   (Germany)

Author keywords

Atherosclerosis; Endothelin; Natriuretic peptides; Vasoconstriction

Indexed keywords

CANDOXATRIL; ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME; MEMBRANE METALLOENDOPEPTIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; ENZYME INHIBITION; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT;

EID: 0034712692     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.16.1976     Document Type: Article

References (38)

1. Hirata Y, Takagi Y, Fukuda Y, Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis. 1989;78:225-228.
2. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
3. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med. 1991;325:997-1001.
4. Kimura S, Kasuya Y, Sawamura T, Shinimi O, Sugita Y, Yanagisawa M, Goto K, Masaki T. Conversion of big endothelin-1 to 21-residue endothelin-1 is essential for expression of full vasoconstrictor activity: structure-activity relationships of big endothelin-1. J Cardiovasc Pharmacol. 1989;13:S5-S7,S18.
5. Opgenorth TJ, Wu-Wong JR, Shiosaki K. Endothelin-converting enzymes. FASEB J. 1992;6:2653-2659.
6. Schmidt M, Kroger B, Jacob E, Seulberger H, Subkowski T, Otter R, Meyer T, Schmalzing G, Hillen H. Molecular characterization of human and bovine endothelin converting enzyme (ECE-1). FEBS Lett. 1994;356: 238-243.
7. Lambert GL, Barker S, Corder R. Comparison of the regulation of endothelin-2 and endothelin-converting enzyme-1 b [correction of beta] by forskolin and TNF-alpha in ACHN cells [published erratum appears in J Cardiovasc Pharmacol. 1998;32:168]. J Cardiovasc Pharmacol. 1998; 31:S49-S51.
8. Minamino T, Kurihara H, Takahashi M, Shimada K, Maemura K, Oda H, Ishikawa T, Uchiyama T, Tanzawa K, Yazaki Y. Endothelin-converting enzyme expression in the rat vascular injury model and human coronary atherosclerosis [published erratum appears in Circulation. 1997;95:1975]. Circulation. 1997;95:221-230.
9. Rossi GP, Colonna S, Pavan E, Albertin G, Della Rocca F, Gerosa G, Csasratto D, Sartore S, Pauletto P, Pessina AC. Endothelin-1 and its mRNA in the wall layers of human arteries ex vivo. Circulation. 1999; 99:1147-1155.
10. Hirata K, Akita H, Yokoyama M, Watanabe Y. Impaired vasodilatory response to atrial natriuretic peptide during atherosclerosis progression. Arterioscler Thromb. 1992;12:99-105.
11. Itoh H, Pratt RE, Dzau VJ. Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. J Clin Invest. 1990;86: 1690-1697.
12. Grantham JA, Burnett JC Jr. Natriuretic peptides in cardiovascular disease: a focus on congestive heart failure. In: Levins SA, ed. Contemporary Endocrinology: The Natriuretic Peptides. Totowa, NJ: Humana Press Inc; 1997.
13. Uemasu J, Matsumoto H, Kitano M, Kawasaki H. Suppression of plasma endothelin-1 level by alpha-human atrial natriuretic peptide and angiotensin converting enzyme inhibition in normal men. Life Sci. 1993;53: 969-974.
14. Neuser D, Stasch JP, Knorr A, Kazda S. Inhibition by atrial natriuretic peptide of endothelin-1-stimulated proliferation of vascular smooth-muscle cells. J Cardiovasc Pharmacol. 1993;22:S257-S261.
15. Hanehira T, Kohno M, Yoshikawa J. Endothelin production in cultured vascular smooth muscle cells: modulation by the atrial, brain, and C-type natriuretic peptide system. Metabolism. 1997;46:487-493.
16. Kugiyama K, Sugiyama S, Matsumura T, Ohta Y, Doi H, Yasue H. Suppression of atherosclerotic changes in cholesterol-fed rabbits treated with an oral inhibitor of neutral endopeptidase 24.11 (EC 3.4.24.11). Anerioscler Thromb Vasc Biol. 1996;16:1080-1087.
17. Grantham JA, Schirger JA, Williamson EE, Heublein DM, Wennberg PW, Kirchengast M, Muenter K, Subkowski T, Burnett JC Jr. Enhanced endothelin-converting enzyme immunoreactivity in early atherosclerosis. J Cardiovasc Pharmacol. 1998;31:S22-S26.
18. Danilewicz JC, Barclay PL, Barnish IT, Brown D, Campbell SF, James K, Samuels GM, Terrett NK, Wythes MJ. UK-69,578, a novel inhibitor of EC 3.4.24.11 which increases endogenous ANF levels and is natriuretic and diuretic. Biochem Biophys Res Commun. 1989;164:58-65.
19. Borgeson DD, Grantham JA, Williamson EE, Luchner A, Redfield MM, Opgenorth TJ, Burnett JC Jr. Chronic oral endothelin type A receptor antagonism in experimental heart failure. Hypertension. 1998;31: 766-770.
20. Grantham JA, Borgeson DD, Burnett JC Jr. BNP: pathophysiological and potential therapeutic roles in acute congestive heart failure. Am J Physiol. 1997;272:R1077-R1083.
21. Brattsand R. Distribution of cholesterol and triglycerides among lipoprotein fractions in fat-fed rabbits at different levels of serum cholesterol. Atherosclerosis. 1976;23:97-110.
22. Roach MR, Fletcher J, Cornhill JF. The effect of the duration of cholesterol feeding on the development of sudanophilic lesions in the rabbit aorta. Atherosclerosis. 1976;25:1-11.
23. Salomone OA, Elliott PM, Calvino R, Holt D, Kaski JC. Plasma immunoreactive endothelin concentration correlates with severity of coronary artery disease in patients with stable angina pectoris and normal ventricular function. J Am Coll Cardiol. 1996;28:14-19.
24. Shimada K, Takahashi M, Tanzawa K. Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. J Biol Chem. 1994;269:18275-18278.
25. Shimada K, Takahashi M, Ikeda M, Tanzawa K. Identification and characterization of two isoforms of an endothelin-converting enzyme-1. FEBS Lett. 1995;371:140-144.
26. Shimada K, Matsushita Y, Wakabayashi K, Takahashi M, Matsubara A, lijima Y, Tanzawa K. Cloning and functional expression of human endothelin-converting enzyme cDNA. Biochem Biophys Res Commun. 1995;207:807-812.
27. Subkowski T, Hillen H, Kroger B, Schmidt M. Monoclonal antibodies against human endothelin-converting enzyme-1. J Immunoassay. 1998; 19:75-93.
28. Suenobo N, Shichiri M, Iwashina M, Marumo F, Hirata Y. Natriuretic peptides and nitric oxide indude endothelial apoptosis via cGMP-dependent mechanism. Arterioscler Thromb Vasc Biol. 1999;19: 140-146.
29. Ehrenreich H, Anderson RW, Fox CH, Rieckmann P, Hoffman GS, Travis WD, Coligan JE, Kehrl JH, Fauci AS. Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med. 1990;172:1741-1748.
30. He Y, Kwan WC, Steinbrecher UP. Effects of oxidized low density lipoprotein on endothelin secretion by cultured endothelial cells and macrophages. Atherosclerosis. 1996;119:107-118.
31. Achmad TH, Rao GS. Chemotaxis of human blood monocytes toward endothelin-1 and the influence of calcium channel blockers. Biochem Biophys Res Commun. 1992;189:994-1000.
32. Schwenke DC. Comparison of aorta and pulmonary artery, I: early cholesterol accumulation and relative susceptibility to atheromatous lesions. Circ Res. 1997;81:338-345.
33. Hu RM, Levin ER, Pedram A, Frank HJ. Atrial natriuretic peptide inhibits the production and secretion of endothelin from cultured endothelial cells: mediation through the C receptor. J Biol Chem. 1992;267:17384-17389.
34. Danilewicz JC, Barclay PL, Barnish IT. UK-69578, a novel inhibitor of EC 3.4.24.11 which increases endogenous ANF levels and is natriuretic and diuretic. Biochem Biophys Res Commun. 1989;164:58-65.
35. Boulanger CM, Tanner FC, Bea ML, Hahn AW, Werner A, Luscher TF. Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ Res. 1992;70: 1191-1197.
36. Jougasaki M, Kugiyama K, Saito Y, Nakao K, Imura H, Yasue H. Suppression of endothelin-1 secretion by lysophosphatidylcholine in oxidized low density lipoprotein in cultured vascular endothelial cells. Circ Res. 1992;71:614-619.
37. Hasdai D, Holmes DR Jr, Garratt KN, Edwards WD, Lerman A. Mechanical pressure and stretch release endothelin-1 from human atherosclerotic coronary arteries in vivo. Circulation. 1997;95:357-362.
38. McDowell G, Coutie W, Shaw C, Buchanan KD, Struthers AD, Nicholls DP. The effect of the neutral endopeptidase inhibitor drug, Candoxatril, on circulating levels of two of the most potent vasoactive peptides. Br J Clin Pharmacol. 1997;43:329-332.